PD-1 therapy plus chemotherapy before stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 79, and you can be any gender.
- Your diagnosis is stomach or gastroesophageal junction adenocarcinoma confirmed by biopsy.
- Your cancer stage is one of these before randomization: T3/4a with certain lymph node findings or T2 with N1–N3, and there is no distant spread (M0).
- You can provide enough tumor tissue for required lab tests (including PD-L1, TMB, immune cells, and MSI/dMMR/EBV).
- Your health status is good enough for treatment (ECOG 0–1).
- Your blood and organ tests are within limits (for example, white blood cells, platelets, hemoglobin, liver tests, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.